Study guide

4.3 Clinical Toxicology, Overdose Management, and Antidotes

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

4.3 Clinical Toxicology, Overdose Management, and Antidotes

Key Takeaways Explain This Topic AI

Single-dose activated charcoal (1 g/kg) is most effective within 1 to 2 hours of toxic ingestion, but is ineffective for heavy metals, lithium, toxic alcohols, and caustics.

Acetaminophen toxicity results from CYP2E1-mediated formation of NAPQI depleting hepatic glutathione; intravenous N-acetylcysteine (NAC) acts as a glutathione precursor and must be guided by the Rumack-Matthew nomogram.

Salicylate poisoning produces a mixed respiratory alkalosis and high anion gap metabolic acidosis; management centers on urinary alkalinization with sodium bicarbonate and mandatory potassium repletion.

Toxic alcohols require early differentiation: methanol produces blinding retinal and putaminal injury from formic acid, whereas ethylene glycol causes acute kidney injury from calcium oxalate crystallization; both are treated with fomepizole.

Serotonin syndrome is defined by neuromuscular clonus and hyperreflexia triggered by serotonergic excess, whereas neuroleptic malignant syndrome (NMS) is characterized by lead-pipe rigidity, hyporeflexia, and slow onset from dopamine blockade.

Last updated: August 2026

4.3 Clinical Toxicology, Overdose Management, and Antidotes

Clinical toxicology encompasses the rapid evaluation, resuscitation, diagnosis, and antidote-directed management of drug overdoses and chemical poisonings. The PEBC Evaluating Examination frequently tests toxic mechanisms, toxidrome differentiation, decontamination limits, and specific antidote pharmacotherapy.

1. General Principles of Resuscitation and Decontamination

Emergency toxicological stabilization prioritizes the clinical "ABCDEs" (Airway, Breathing, Circulation, Disability, Exposure), correction of hypoglycemia (dextrose), thiamine administration in suspected alcoholism/Wernicke encephalopathy, and targeted antidote delivery. +--------------------------------------------------------------------------------------+

  • | GASTROINTESTINAL DECONTAMINATION MODALITIES |
  • +--------------------------------------------------------------------------------------+
  • | 1. Single-Dose Activated Charcoal (SDAC: 1 g/kg PO/NG within 1-2 hours) |
  • | - Ineffective: Iron, Lithium, Lead, Toxic Alcohols, Strong Acids/Alkalis (PHAILS)|
  • | - Contraindicated: Unprotected airway, bowel perforation, hydrocarbon ingestion |
  • | |
  • | 2. Multiple-Dose Activated Charcoal (MDAC: 0.5 g/kg q2-4h) |
  • | - Effective for: Carbamazepine, Dapsone, Phenobarbital, Quinine, Theophylline |
  • | |
  • | 3. Whole Bowel Irrigation (WBI: PEG-ELS 1.5-2 L/h until clear effluent) |
  • | - Indications: Sustained-release tablets, Iron, Lithium, Illicit Body Packers |
  • | |
  • | 4. Urinary Alkalinization (IV NaHCO3 targeting urine pH 7.5 - 8.5) |
  • | - Indications: Salicylates, Phenobarbital, Methotrexate |
  • | - Prerequisite: Must correct hypokalemia (K+) to prevent paradoxical aciduria |
  • +--------------------------------------------------------------------------------------+
  • Extracorporeal Enhanced Elimination (Hemodialysis)

Hemodialysis efficiently eliminates toxins with low molecular weight ( < 500 Da <500\text{ Da} < 500 Da ), low protein binding ( < 70 − 80 % <70-80\% < 70 − 80% ), high water solubility, and a small apparent volume of distribution ( V d < 1 L/kg V_d < 1\text{ L/kg} V d ​ < 1 L/kg ): Indications for Hemodialysis ("I STUMBLE") : { I Isopropanol (refractory hypotension) S Salicylates (level > 6.5 − 7.2 mmol/L [ 90 − 100 mg/dL], coma, ARDS) T Theophylline (acute level > 500 μ mol/L [ 90 − 100 mg/L]) U Uremia M Methanol (level > 15 − 20 mmol/L, visual defects, severe acidosis) B Barbiturates (phenobarbital with refractory shock/coma) L Lithium (level > 4.0 mmol/L acute, or > 2.5 chronic with neurotoxicity) E Ethylene Glycol (level > 15 − 20 mmol/L, renal failure, severe acidosis) \mathbf{\text{Indications for Hemodialysis ("I STUMBLE")}}: \begin{cases}

  • \mathbf{I} & \text{Isopropanol (refractory hypotension)} \\
  • \mathbf{S} & \text{Salicylates (level } > 6.5-7.2\text{ mmol/L [}90-100\text{ mg/dL], coma, ARDS)} \\
  • \mathbf{T} & \text{Theophylline (acute level } > 500\text{ }\mu\text{mol/L [}90-100\text{ mg/L])} \\
  • \mathbf{U} & \text{Uremia} \\
  • \mathbf{M} & \text{Methanol (level } > 15-20\text{ mmol/L, visual defects, severe acidosis)} \\
  • \mathbf{B} & \text{Barbiturates (phenobarbital with refractory shock/coma)} \\
  • \mathbf{L} & \text{Lithium (level } > 4.0\text{ mmol/L acute, or } > 2.5\text{ chronic with neurotoxicity)} \\
  • \mathbf{E} & \text{Ethylene Glycol (level } > 15-20\text{ mmol/L, renal failure, severe acidosis)}

\end{cases} Indications for Hemodialysis ("I STUMBLE") : ⎩ ⎨ ⎧ ​ I S T U M B L E ​ Isopropanol (refractory hypotension) Salicylates (level > 6.5 − 7.2 mmol/L [ 90 − 100 mg/dL], coma, ARDS) Theophylline (acute level > 500 μ mol/L [ 90 − 100 mg/L]) Uremia Methanol (level > 15 − 20 mmol/L, visual defects, severe acidosis) Barbiturates (phenobarbital with refractory shock/coma) Lithium (level > 4.0 mmol/L acute, or > 2.5 chronic with neurotoxicity) Ethylene Glycol (level > 15 − 20 mmol/L, renal failure, severe acidosis) ​

2. Clinical Toxidrome Differentiation

A toxidrome is a constellation of clinical signs and symptoms characteristic of a specific pharmacological class of poison:

Toxidrome Vital Signs Mental Status Pupils Skin / Mucosa Bowel / Bladder Hallmark Diagnostic Features

Anticholinergic ↑ \uparrow ↑ HR, ↑ \uparrow ↑ BP, ↑ \uparrow ↑ Temp Agitated delirium, hallucinations Mydriasis (dilated, sluggish) Anhidrosis (dry skin) , flushed, dry mucosa ↓ \downarrow ↓ Bowel sounds, urinary retention "Blind as a bat, mad as a hatter, red as a beet, hot as a hare, dry as a bone." Axillae are bone dry.

Cholinergic ↓ \downarrow ↓ HR (or ↑ \uparrow ↑ ), ↓ \downarrow ↓ BP Confusion, coma, seizures Miosis (pinpoint) Diaphoresis (wet skin) , salivation, lacrimation Diarrhea, hyperactive sounds, incontinence DUMBELS / SLUDGEM : Salivation, Lacrimation, Urination, Defecation, GI cramping, Emesis, Miosis, Bronchorrhea.

Sympathomimetic ↑ ↑ \uparrow\uparrow ↑↑ HR, ↑ ↑ \uparrow\uparrow ↑↑ BP, ↑ ↑ \uparrow\uparrow ↑↑ Temp Hyperalert, paranoia, agitation Mydriasis (reactive) Diaphoresis (wet skin) , warm Normal / Hyperactive sounds Distinguished from anticholinergic by prominent diaphoresis and moist axillae (cocaine, amphetamines).

Opioid ↓ \downarrow ↓ HR, ↓ \downarrow ↓ BP, ↓ ↓ \downarrow\downarrow ↓↓ RR, ↓ \downarrow ↓ Temp Sedation, coma Miosis (pinpoint) Cool, pale ↓ \downarrow ↓ Bowel sounds, constipation Classic triad: CNS depression + Respiratory depression + Pinpoint miosis (Naloxone responsive).

Sedative-Hypnotic Mild ↓ \downarrow ↓ HR, ↓ \downarrow ↓ BP, mild ↓ \downarrow ↓ RR Stupor, coma, ataxia Normal / Variable Normal ↓ \downarrow ↓ Bowel sounds CNS depression with relatively stable vital signs and absence of pinpoint pupils (benzodiazepines, barbiturates).

Serotonin Syndrome vs. Neuroleptic Malignant Syndrome vs. Malignant Hyperthermia +--------------------------------------------------------------------------------------+

  • | HYPERTHERMIC TOXICOLOGICAL EMERGENCIES MATRIX |
  • +--------------------------------------------------------------------------------------+
  • | SEROTONIN SYNDROME (SS): |
  • | - Etiology : Serotonergic excess (SSRIs + MAOIs, TCAs, Tramadol, Linezolid, Fentanyl) |
  • | - Onset : Rapid (<24 hours) |
  • | - Features : Spontaneous / Inducible CLONUS, Hyperreflexia (legs > arms), Diaphoresis|
  • | - Treatment: Stop agents, Benzodiazepines, Cyproheptadine (5-HT2A antagonist) |
  • | |
  • | NEUROLEPTIC MALIGNANT SYNDROME (NMS): |
  • | - Etiology : Dopamine D2 blockade (Antipsychotics) or DA agonist withdrawal |
  • | - Onset : Gradual (days to weeks) |
  • | - Features : "LEAD-PIPE" Rigidity, Hyporeflexia, Extreme Hyperthermia, High CK / WBC |
  • | - Treatment: Stop neuroleptic, ICU cooling, Bromocriptine (DA agonist), Dantrolene |
  • | |
  • | MALIGNANT HYPERTHERMIA (MH): |
  • | - Etiology : RYR1 receptor mutation triggered by Volatile Anesthetics / Succinylcholine
  • | - Features : Masseter spasm, rapid hyperthermia, metabolic acidosis, rhabdomyolysis |
  • | - Treatment: Discontinue trigger, 100% O2, IV Dantrolene (1-2.5 mg/kg boluses) |
  • +--------------------------------------------------------------------------------------+
  • 3. High-Yield Specific Toxicities and Mechanisms
  • Acetaminophen (APAP) Hepatotoxicity and N-Acetylcysteine

Acetaminophen is metabolized at therapeutic doses via glucuronidation ( 50 − 60 % 50-60\% 50 − 60% ) and sulfation ( 30 − 40 % 30-40\% 30 − 40% ). A small fraction ( < 10 % <10\% < 10% ) is oxidized by CYP2E1 to the highly reactive electrophile N-acetyl-p-benzoquinone imine (NAPQI) , which is rapidly detoxified by conjugation with endogenous hepatic glutathione . [Acetaminophen (Toxic Ingestion)]

  • |
  • +----------------------+----------------------+
  • | (Saturated Pathways) | (Shunted Pathway)
  • v v
  • [Phase II Glucuronide / Sulfate] [CYP2E1]
  • (Non-Toxic) |
  • v
  • [NAPQI]
  • |
  • +-----------------------------+-----------------------------+
  • | |
  • v (+ Hepatic Glutathione / NAC) v (Glutathione Stores <30%)
  • [Mercapturic Acid / Cysteine Conjugate] [Covalent Binding to Hepatocyte Proteins]
  • (Non-Toxic Urine Excretion) |
  • v
  • [Centrilobular Hepatic Necrosis]

The Rumack-Matthew Nomogram : Evaluates hepatotoxicity risk strictly for single acute ingestions with known ingestion time between 4 4 4 and 24 hours 24\text{ hours} 24 hours .

The Canadian treatment line starts at 1000 μ mol/L 1000\text{ }\mu\text{mol/L} 1000 μ mol/L ( 150 mcg/mL 150\text{ mcg/mL} 150 mcg/mL ) at 4 hours 4\text{ hours} 4 hours post-ingestion.

N-Acetylcysteine (NAC) Mechanism : Replenishes hepatic glutathione stores, serves as a direct glutathione surrogate, enhances non-toxic sulfation, and improves microcirculatory perfusion.

Dosing Protocols : Intravenous 21-hour 3-bag protocol ( 150 mg/kg 150\text{ mg/kg} 150 mg/kg over 1 h 1\text{ h} 1 h , 50 mg/kg 50\text{ mg/kg} 50 mg/kg over 4 h 4\text{ h} 4 h , 100 mg/kg 100\text{ mg/kg} 100 mg/kg over 16 h 16\text{ h} 16 h ) or simplified 2-bag protocol ( 200 mg/kg 200\text{ mg/kg} 200 mg/kg over 4 h 4\text{ h} 4 h , 100 mg/kg 100\text{ mg/kg} 100 mg/kg over 16 h 16\text{ h} 16 h ). NAC is continued beyond standard infusion until APAP is undetectable, ALT/AST are normal or clearly declining, and INR < 1.5 <1.5 < 1.5 .

Salicylate (Aspirin) Toxicity

Salicylates exhibit complex biphasic acid-base derangements:

Early Phase : Direct stimulation of the medullary respiratory center causes hyperventilation and a primary respiratory alkalosis .

Late Phase : Uncoupling of mitochondrial oxidative phosphorylation, inhibition of Krebs cycle dehydrogenases, and stimulation of lipolysis lead to accumulation of lactic acid, pyruvate, and ketoacids, producing a primary high anion gap metabolic acidosis .

Net Clinical State : Mixed Primary Respiratory Alkalosis and Primary High Anion Gap Metabolic Alkalosis .

Management : Volume resuscitation, IV Sodium Bicarbonate infusion (targets urine pH 7.5 − 8.5 \text{pH } 7.5-8.5 pH 7.5 − 8.5 to trap ionized salicylate in tubular fluid), mandatory potassium repletion , and emergent hemodialysis for severe poisonings (salicylate > 6.5 − 7.2 mmol/L >6.5-7.2\text{ mmol/L} > 6.5 − 7.2 mmol/L , altered mental status, pulmonary edema, or renal failure).

Toxic Alcohols: Methanol vs. Ethylene Glycol vs. Isopropanol Osmolal Gap = Measured Osmolality − ( 2 ⋅ [ Na + ] + [ Glucose ] + [ Urea ] ) ( Normal < 10 − 15 mOsm/kg ) \text{Osmolal Gap} = \text{Measured Osmolality} - \left(2 \cdot [\text{Na}^+] + [\text{Glucose}] + [\text{Urea}]\right) \quad (\text{Normal } < 10-15\text{ mOsm/kg}) Osmolal Gap = Measured Osmolality − ( 2 ⋅ [ Na + ] + [ Glucose ] + [ Urea ] ) ( Normal < 10 − 15 mOsm/kg )

Feature Methanol Ethylene Glycol Isopropyl Alcohol

Common Sources Windshield washer fluid, bootleg liquor Engine antifreeze / coolants Rubbing alcohol, hand sanitizers

  • Metabolic Enzyme Alcohol Dehydrogenase (ADH) Alcohol Dehydrogenase (ADH) Alcohol Dehydrogenase (ADH)
  • Toxic Metabolite Formic Acid (Formate) Glycolic Acid → \to → Oxalic Acid Acetone (Ketone, not an organic acid)

Hallmark Target Toxicity Optic papillitis, retinal edema ("snowstorm" vision), putaminal necrosis Calcium oxalate crystal nephropathy (ATN), hypocalcemia, QTc prolongation Hemorrhagic gastritis, CNS depression without metabolic acidosis

Acid-Base Profile High Anion Gap Metabolic Acidosis + Elevated Osmolal Gap High Anion Gap Metabolic Acidosis + Elevated Osmolal Gap Elevated Osmolal Gap + Ketonemia WITHOUT Metabolic Acidosis

Specific Antidote Fomepizole (or Ethanol) + IV Folinic / Folic Acid Fomepizole (or Ethanol) + IV Thiamine & Pyridoxine Supportive care; Fomepizole is NOT indicated (acetone is not toxic)

4. Comprehensive Antidote Master Table

Toxic Substance / Overdose Specific Antidote Antidote Mechanism of Action Clinical Pearls & Administration

Acetaminophen N-Acetylcysteine (NAC) Replenishes glutathione; direct antioxidant and NAPQI scavenger Nomogram guided; IV 21-hour or simplified 2-bag protocol

Opioids Naloxone Competitive antagonist at μ \mu μ , κ \kappa κ , δ \delta δ opioid receptors Titrate to restore respiratory rate (target 10 − 12 bpm 10-12\text{ bpm} 10 − 12 bpm ), not full arousal; short t 1 / 2 t_{1/2} t 1/2 ​ ( 30 − 90 min 30-90\text{ min} 30 − 90 min ) requires repeat dosing

Benzodiazepines Flumazenil Competitive antagonist at GABA A \text{GABA}_A GABA A ​ benzodiazepine site Caution : Contraindicated in chronic benzo users or co-ingested proconvulsants/TCAs (precipitates refractory seizures/status)

Beta-Blockers Glucagon Stimulates myocardial adenylyl cyclase via non-adrenergic receptors → ↑ \to \uparrow →↑ cAMP First-line: Glucagon ( 3 − 10 mg 3-10\text{ mg} 3 − 10 mg IV bolus + infusion); High-Dose Insulin-Euglycemia Therapy (HIET); Lipid Emulsion

Calcium Channel Blockers Calcium Chloride / Gluconate + HIET Overcomes Ca 2 + \text{Ca}^{2+} Ca 2 + channel blockade; HIET provides direct myocardial carbohydrate fuel Calcium IV boluses; High-Dose Insulin ( 1 unit/kg 1\text{ unit/kg} 1 unit/kg bolus + 1 − 10 units/kg/h + 1-10\text{ units/kg/h} + 1 − 10 units/kg/h infusion) with dextrose and K + \text{K}^+ K + support

Digoxin Digoxin-Specific Fab Fragments (DigiFab) Binds free intravascular digoxin molecules; complex excreted renally Indications: Life-threatening arrhythmia, hyperkalemia ( [ K + ] > 5.0 mmol/L [\text{K}^+] > 5.0\text{ mmol/L} [ K + ] > 5.0 mmol/L ), acute ingestion > 10 mg >10\text{ mg} > 10 mg ( 4 mg 4\text{ mg} 4 mg in child)

Toxic Alcohols (Methanol / Ethylene Glycol) Fomepizole (4-Methylpyrazole) Potent competitive inhibitor of Alcohol Dehydrogenase (ADH, > 8000 × >8000\times > 8000 × affinity vs ethanol) Loading dose 15 mg/kg 15\text{ mg/kg} 15 mg/kg IV over 30 min 30\text{ min} 30 min , then 10 mg/kg 10\text{ mg/kg} 10 mg/kg q12h × 4 \times 4 × 4 doses; hemodialysis clears parent alcohol and metabolites

Cyanide Hydroxocobalamin (Cyanokit) Cobalt ion chelates cyanide, forming non-toxic cyanocobalamin (Vitamin B 12 \text{B}_{12} B 12 ​ ) excreted in urine 5 g 5\text{ g} 5 g IV over 15 min 15\text{ min} 15 min ; turns skin/urine deep red; alternative: Sodium nitrite + + + Sodium thiosulfate

Carbon Monoxide 100% Normobaric / Hyperbaric O 2 \text{O}_2 O 2 ​ Competitively displaces CO from hemoglobin, reducing carboxyhemoglobin half-life Half-life in room air: 300 min 300\text{ min} 300 min ; on 100 % O 2 100\%\ \text{O}_2 100% O 2 ​ : 90 min 90\text{ min} 90 min ; Hyperbaric O 2 \text{O}_2 O 2 ​ ( 2.8 − 3.0 atm 2.8-3.0\text{ atm} 2.8 − 3.0 atm ): 20 − 30 min 20-30\text{ min} 20 − 30 min

Iron Deferoxamine Chelates ferric iron ( Fe 3 + \text{Fe}^{3+} Fe 3 + ) to form water-soluble ferrioxamine Excreted in urine, turning it classic "vin rosé" (red-orange); indicated for shock, severe acidosis, or iron > 90 μ mol/L >90\text{ }\mu\text{mol/L} > 90 μ mol/L

Lead, Arsenic, Mercury Dimercaprol (BAL), Succimer (DMSA) Sulfhydryl donor that chelates heavy metals Succimer is water-soluble oral chelator; BAL is IM in peanut oil (check peanut allergy)

Copper (Wilson's Disease / Poisoning) Penicillamine, Trientine Chelates copper ions; enhances urinary excretion Co-administer pyridoxine (vitamin B 6 \text{B}_6 B 6 ​ ) with penicillamine

Sulfonylureas Octreotide Somatostatin analog; suppresses glucose-stimulated insulin secretion from β \beta β -cells 50 − 100 μ g 50-100\text{ }\mu\text{g} 50 − 100 μ g SC/IV q8-12h; prevents rebound hypoglycemia associated with repeated dextrose boluses alone

Isoniazid (INH) Pyridoxine (Vitamin B 6 \text{B}_6 B 6 ​ ) Restores GABA synthesis by bypassing inhibited pyridoxal-5-phosphate Dose equals gram-for-gram of INH ingested (or empiric 5 g 5\text{ g} 5 g IV); terminates INH-induced refractory status epilepticus

Anticholinergics Physostigmine Tertiary amine acetylcholinesterase inhibitor; crosses blood-brain barrier Reverses central and peripheral anticholinergic delirium; contraindicated in TCA overdose (triggers asystole)

Local Anesthetic Toxicity (LAST) 20% Intravenous Lipid Emulsion (ILE) "Lipid sink" partitions lipophilic local anesthetics (bupivacaine) from cardiac tissue 1.5 mL/kg 1.5\text{ mL/kg} 1.5 mL/kg IV bolus, then 0.25 mL/kg/min 0.25\text{ mL/kg/min} 0.25 mL/kg/min infusion; indicated for refractory cardiovascular collapse

Heparin / Enoxaparin Protamine Sulfate Positively charged basic peptide that neutralizes negatively charged heparin 1 mg 1\text{ mg} 1 mg protamine neutralizes 100 units 100\text{ units} 100 units unfractionated heparin; neutralizes ∼ 60 − 75 % \sim 60-75\% ∼ 60 − 75% of enoxaparin anti-Xa activity

Direct Factor Xa Inhibitors Andexanet Alfa / 4-Factor PCC Decoy protein binding anti-Xa agents (Andexanet) or concentrates coagulation factors Indicated for life-threatening bleeding on apixaban or rivaroxaban

Dabigatran Idarucizumab (Praxbind) Humanized Fab fragment with 350 × 350\times 350 × higher affinity for dabigatran than thrombin 5 g 5\text{ g} 5 g IV ( 2 × 2.5 g 2 \times 2.5\text{ g} 2 × 2.5 g vials) provides immediate reversal for emergency surgery or life-threatening hemorrhage